L
L. Leroy
Researcher at Institut Gustave Roussy
Publications - 13
Citations - 1102
L. Leroy is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 6, co-authored 9 publications receiving 751 citations.
Papers
More filters
Journal ArticleDOI
Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.
Laura Mezquita,Edouard Auclin,Roberto Ferrara,Melinda Charrier,Jordi Remon,David Planchard,Santiago Ponce,L. Arés,L. Leroy,Clarisse Audigier-Valette,Enriqueta Felip,Jorge Zeron-Medina,Pilar Garrido,Solenn Brosseau,Gérard Zalcman,Julien Mazieres,Caroline Caramela,J. Lahmar,Julien Adam,Nathalie Chaput,Nathalie Chaput,Jean-Charles Soria,Jean-Charles Soria,Benjamin Besse,Benjamin Besse +24 more
TL;DR: Pretreatment LIPI, combining dNLR greater than 3 and LDH greater than upper limit of normal (ULN) was correlated with worse outcomes for ICI, but not for chemotherapy, suggesting that LIPi can serve as a potentially useful tool when selecting ICI treatment.
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
1306PDHyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
Roberto Ferrara,Caroline Caramella,M. Texier,C. Audigier Valette,Laurent Tessonnier,Laura Mezquita,J. Lahmar,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Virginie Westeel,S. Le Moulec,L. Leroy,Boris Duchemann,Remi Veillon,David Planchard,M-E. Boucher,Serge Koscielny,J-C. Soria,Benjamin Besse +19 more
Journal ArticleDOI
Fast-progression (FP), hyper-progression (HPD) and early deaths (ED) in advanced non-small cell lung cancer (NSCLC) patients (pts) upon PD-(L)-1 blockade (IO).
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Solenn Brosseau,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Stéphane Champiat,David Planchard,Jordi Remon,Anas Gazzah,Jean-Charles Soria,Caroline Caramella,Benjamin Besse +19 more
TL;DR: HPD was described in 13.8% of NSCLC pts upon single-agent IO and correlated with high metastatic burden and poor prognosis and other progression (PD) patterns as FP and ED within 12 months.